DK1739166T3 - Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population - Google Patents

Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population

Info

Publication number
DK1739166T3
DK1739166T3 DK05291429.8T DK05291429T DK1739166T3 DK 1739166 T3 DK1739166 T3 DK 1739166T3 DK 05291429 T DK05291429 T DK 05291429T DK 1739166 T3 DK1739166 T3 DK 1739166T3
Authority
DK
Denmark
Prior art keywords
food
leukocyte
population
antigen
pbmc
Prior art date
Application number
DK05291429.8T
Other languages
English (en)
Inventor
Arnaud Foussat
Valerie Brun
Herve Groux
Francoise Cottrez
Original Assignee
Txcell S A
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txcell S A, Inst Nat Sante Rech Med filed Critical Txcell S A
Application granted granted Critical
Publication of DK1739166T3 publication Critical patent/DK1739166T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/46482—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/53—CD2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/50—Coculture with; Conditioned medium produced by invertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK05291429.8T 2005-07-01 2005-07-01 Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population DK1739166T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291429A EP1739166B1 (en) 2005-07-01 2005-07-01 Obtention of food- or auto-antigen specific Tr1 cells from a leukocyte or PBMC population

Publications (1)

Publication Number Publication Date
DK1739166T3 true DK1739166T3 (da) 2011-10-10

Family

ID=36168439

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05291429.8T DK1739166T3 (da) 2005-07-01 2005-07-01 Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population
DK06808973.9T DK1899459T3 (da) 2005-07-01 2006-07-03 Opnåelse af fødevare- eller autoantigenspecifikke tr1-celler fra en leukocyt- eller pbmc-population

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06808973.9T DK1899459T3 (da) 2005-07-01 2006-07-03 Opnåelse af fødevare- eller autoantigenspecifikke tr1-celler fra en leukocyt- eller pbmc-population

Country Status (14)

Country Link
US (1) US7977093B2 (da)
EP (2) EP1739166B1 (da)
JP (2) JP5502322B2 (da)
AT (1) ATE513903T1 (da)
AU (1) AU2006271320B2 (da)
CA (1) CA2613778C (da)
CY (2) CY1112351T1 (da)
DK (2) DK1739166T3 (da)
ES (2) ES2368152T3 (da)
HU (1) HUE029143T2 (da)
PL (2) PL1739166T3 (da)
PT (2) PT1739166E (da)
SI (2) SI1739166T1 (da)
WO (1) WO2007010406A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006285446B2 (en) * 2005-08-31 2013-08-22 Tla Targeted Immunotherapies Ab Treatment of inflammatory bowel disease
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
WO2009050282A1 (en) 2007-10-17 2009-04-23 Txcell Tr1 cells, mesenchymal stem cells and uses thereof
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
EP2113560A1 (en) 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
EP2113254B1 (en) 2008-04-28 2012-08-15 TXCell Compositions for treating an inflammatory auto-immune condition
WO2010000730A1 (en) * 2008-06-30 2010-01-07 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
GB0820397D0 (en) * 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
EP2221364A1 (en) 2009-02-23 2010-08-25 TXCell Compositions for treating an allergic or asthmatic condition
WO2012131419A1 (en) 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
EP2982746A1 (en) 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
WO2019018801A1 (en) * 2017-07-21 2019-01-24 Berkeley Lights Inc. SYNTHETIC SURFACES FOR PRESENTING ANTIGENS, COVALENTLY FUNCTIONALIZED SURFACES, ACTIVATED T CELLS AND USES THEREOF
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
KR102232321B1 (ko) * 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
PL238336B1 (pl) 2019-08-22 2021-08-09 Gdanski Univ Medyczny Sposób otrzymywania in vitro antygenowo-specyficznych limfocytów T regulatorowych

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814838B1 (en) * 1995-03-08 2003-05-14 The Scripps Research Institute Antigen presenting system and activation of t-cells
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells

Also Published As

Publication number Publication date
EP1899459A2 (en) 2008-03-19
WO2007010406A2 (en) 2007-01-25
ES2368152T3 (es) 2011-11-14
PT1739166E (pt) 2011-09-22
ES2578259T3 (es) 2016-07-22
AU2006271320B2 (en) 2012-04-26
CA2613778C (en) 2016-06-07
US20090075372A1 (en) 2009-03-19
CY1112351T1 (el) 2015-12-09
JP2008544760A (ja) 2008-12-11
AU2006271320A1 (en) 2007-01-25
JP5502322B2 (ja) 2014-05-28
CA2613778A1 (en) 2007-01-25
PL1899459T3 (pl) 2016-10-31
EP1899459B1 (en) 2016-03-23
PL1739166T3 (pl) 2012-01-31
CY1117772T1 (el) 2017-05-17
US7977093B2 (en) 2011-07-12
HUE029143T2 (hu) 2017-02-28
EP1739166B1 (en) 2011-06-22
SI1899459T1 (sl) 2016-09-30
DK1899459T3 (da) 2016-07-18
WO2007010406A3 (en) 2007-03-29
PT1899459T (pt) 2016-07-08
JP2013240334A (ja) 2013-12-05
EP1739166A1 (en) 2007-01-03
SI1739166T1 (sl) 2011-11-30
ATE513903T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
DK1739166T3 (da) Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population
Zielinski et al. Dissecting the human immunologic memory for pathogens
WO2006108882A8 (en) In vitro production of a cell population using feeder cells
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
SG152273A1 (en) Pdx1 expressing endoderm
WO2007017915A3 (en) Use of common ϝ chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes.
MX2016016251A (es) Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa.
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
BR0311360A (pt) métodos para expansão e transdiferenciação in vitro de células acinares pancreáticas humanas em células produtoras de insulina
NO20033396L (no) Forbedret in vitro fremgangsmåte for dyrking av mammale celler for autologcelle implantasjon/transplantasjon fremgangsmåter
ATE481476T1 (de) Erzeugung und isolierung antigenspezifischer t- zellen
SG151246A1 (en) Tissue system with undifferentiated stem cells derived from corneal limbus
EA200800996A1 (ru) Способ получения т-клеточной популяции
WO2006124412A3 (en) Methods for the rapid expansion of antigen specific t-cells
WO2005097979A3 (en) Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
ATE496117T1 (de) Hautregenerationssystem
MX2021005481A (es) Metodos para aislar y expandir celulas.
ATE429486T1 (de) Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
WO2005077048A3 (en) Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
DE602005012962D1 (de) Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung
EP2377922A3 (en) PDX1 expressing endoderm
WO2006047426A3 (en) Compositions, methods and systems for preparation of a stem cell-enriched cell population
DE60043781D1 (de) Verwendung allogener zelllinien zur beladung antigen-präsentierender zellen zur auslösung von immunantworten
CY1107952T1 (el) Δενδριτικα κυτταρα ενεργοποιημενα εν τη παρουσια γλυκοκορτικοειδων ορμονων ειναι ικανα να καταστελλουν αντιγονο-ειδικες αποκρισεις κυτταρων
WO2002036748A3 (en) Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells